Report Overview

The UK Mucopolysaccharidosis I Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Mucopolysaccharidosis I (MPS I) is a member of a group of hereditary metabolic diseases known as the mucopolysaccharidoses which, in turn, are part of a larger group of diseases known as lysosomal storage disorders (LSDs). Mutations in IDUA gene cause MPS I. There are seven forms of mucopolysaccharidosis. In individuals with MPS disorders, including MPS I, deficiency or improper functioning of lysosomal enzymes leads to an abnormal accumulation of a particular complex carbohydrate known as glycosaminoglycans (GAGs). When cells cannot break down these glycosaminoglycans they then accumulate within various tissues, such as the bones, joints, brain, spinal cord, heart, spleen, or liver, and this leads to the symptoms that MPS I individuals have.

Generally, most of the affected people appear healthy at birth and experience a period of normal development, followed by a decline in physical and/or mental function. As the condition progresses, it may affect appearance, physical abilities, organ and system functioning, and in most cases, cognitive development.



Market Growth Drivers

The growing necessity for advanced therapeutics will impel companies to launch novel therapies, which in turn, will boost the MPS I treatment market growth in the forthcoming years. Moreover, the growing unmet clinical needs of patients along with better treatment outcomes will spur demand for the MPS I treatment market during the forecast period.

In addition, the increasing R&D by pharmaceutical companies for the mass production of conventional medications or therapies to treat mucopolysaccharidosis, this factor will aid the MPS I treatment market revenue in the foreseeable future.

Market Restraints

The high cost of therapeutics coupled with the poor diagnosis is expected to hinder the growth of the MPS I treatment market during the forecast period. Another key limiting factor is the delay associated with the diagnosis of mucopolysaccharidosis.